Here are the DEF 14A proxy statements from Alto Neuroscience Inc. (ANRO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ANRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANRO filings page.
Alto Neuroscience, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 12, 2026. Stockholders of record as of March 16, 2026, when 31,945,516 common shares were outstanding, can attend and vote online using a control number.
The meeting will elect two Class II directors, Raymond Sanchez, M.D. and Gwill York, to serve until the 2029 annual meeting, ratify Deloitte & Touche LLP as independent auditor for 2026, and approve amendments to the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan.
The equity plan changes would amend the evergreen formulas so that outstanding pre-funded warrants are treated the same as outstanding common shares when calculating the automatic annual increases to each plan’s share reserve. The Board recommends voting “FOR” all four proposals.